EGFR and breast carcinoma: It is noteworthy that in our preclinical orthotopic model, grafted/xenotransplanted human breast CSCs aggravated tumor size, and weight as compared with the breast cancer cells, which was effectively perturbed by the combinatorial administration of the potent EGFR inhibitor, 1e and a low dose of doxorubicin.